Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of semaglutide injection versus Ozempic in type 2 diabetes mellitus
CTR20244501Phase 3Completed
- Sponsor
- Sinopep-Allsino Biopharmaceutical
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Sinopep-Allsino Biopharmaceutical. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244501.